Table 1 Patient characteristics
| Â | 6 FEC 100 | 3 FEC/3D |
|---|---|---|
Total number of patients (154) | 84 | 70 |
Median age (range) | 43.5 (28–58) | 44 29–53) |
Patients < 40 years (n = 39) | 18 (21.5 %) | 21 (30 %) |
Patients ≥ 40 years (n = 115) | 66 (78 %) | 49 (70 %) (p = 0.08) |
Hormone receptor status | Â | Â |
Positive (ER and/or PR) | 61 (72.6 %) | 53 (75.9 %) |
Negative (ER and PR) | 23 (27.4 %) | 17 (24.1 %) |
ER positive | 60 (71.4 %) | 52 (74.2 %) |
ER negative | 24 (28.5 %) | 18 (25.7 %) |
PR positive | 50 (59.5 %) | 44 (62.8 %) |
PR negative | 34 (40.4 %) | 26 (37.1 %) |
Median tumor size (range) | Â | Â |
Tumor grade | Â | Â |
I | 8 (9.5 %) | 6 (8.6 %) |
II | 34 (40.5 %) | 30 (42.8 %) |
III | 42 (50 %) | 34 (48.6 %) |
Number of metastatic lymph nodes | Â | Â |
< 4 | 66 (78.6 %) | 53 (75.9 %) |
≥ 4 | 18 (21.4 %) | 17 (24.1 %) |
Tumor size | Â | Â |
T1 | 25 (29.7 %) | 21 (30 %) |
T2 | 50 (59.5 %) | 42 (60 %) |
T3 | 9 (10.8 %) | 7 (10 %) |